NANO Relative Valuation - Nanobiotix SA - Alpha Spread

Nanobiotix SA
PAR:NANO

Watchlist Manager
Nanobiotix SA Logo
Nanobiotix SA
PAR:NANO
Watchlist
Price: 4.646 EUR 4.31% Market Closed
Market Cap: 220.2m EUR
Have any thoughts about
Nanobiotix SA?
Write Note

Relative Value

The Relative Value of one NANO stock under the Base Case scenario is 6.822 EUR. Compared to the current market price of 4.646 EUR, Nanobiotix SA is Undervalued by 32%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NANO Relative Value
Base Case
6.822 EUR
Undervaluation 32%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
69
vs Industry
53
Median 3Y
7.5
Median 5Y
2 031.1
Industry
7.7
Forward
7.6
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-4.4
Industry
23.9
Forward
-5.2
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-6
Industry
22.2
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-7.5
Industry
24
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-3.4
Industry
2.5
vs History
69
vs Industry
49
Median 3Y
6.5
Median 5Y
2 180.3
Industry
7.4
Forward
6.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.5
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-4.4
Industry
5.1
Forward
-4.6
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-4.2
Industry
4.7
Forward
-4.9
vs History
vs Industry
Median 3Y
-6.8
Median 5Y
-5.7
Industry
6.6
vs History
vs Industry
Median 3Y
-6.7
Median 5Y
-5.5
Industry
4.7
vs History
50
vs Industry
21
Median 3Y
11
Median 5Y
10
Industry
4.7

Multiples Across Competitors

NANO Competitors Multiples
Nanobiotix SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Nanobiotix SA
PAR:NANO
218.9m EUR 7.3 -5.5 -7.4 -7
US
Abbvie Inc
NYSE:ABBV
341.9B USD 6.2 64.6 15.8 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
127.8B USD 9.5 29.6 25.9 28.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.3B USD 11.9 -251.7 26.8 28.1
US
Gilead Sciences Inc
NASDAQ:GILD
104.5B USD 3.8 99.3 9.4 12
US
Epizyme Inc
F:EPE
94.1B EUR 1 981.8 -505.7 -550.7 -536
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.7 22.4 27.9
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.5 -63 -56.9
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.4B USD 15.1 -485.3 213.7 328.9
P/E Multiple
Earnings Growth
FR
Nanobiotix SA
PAR:NANO
Average P/E: 57.5
Negative Multiple: -5.5
N/A
US
Abbvie Inc
NYSE:ABBV
64.6
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.6
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -251.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
36.7
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -485.3 N/A
EV/EBITDA Multiple
EBITDA Growth
FR
Nanobiotix SA
PAR:NANO
Average EV/EBITDA: 47.7
Negative Multiple: -7.4
N/A
US
Abbvie Inc
NYSE:ABBV
15.8
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.9
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -550.7 N/A
AU
CSL Ltd
ASX:CSL
22.4
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -63 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
213.7
N/A
EV/EBIT Multiple
EBIT Growth
FR
Nanobiotix SA
PAR:NANO
Average EV/EBIT: 69.5
Negative Multiple: -7
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.6
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
28.7
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
38%
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -536 N/A
AU
CSL Ltd
ASX:CSL
27.9
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
328.9
N/A

See Also

Discover More
Back to Top